FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

Article Link: FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

DUBLIN, June 21, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental biologics application (sBLA) for Botox for the treatment of pediatric patients (2 to…

Source: FDA New Drug Approvals